I
130.14
-0.93 (-0.71%)
| Previous Close | 131.07 |
| Open | 131.19 |
| Volume | 469,697 |
| Avg. Volume (3M) | 1,484,887 |
| Market Cap | 10,341,484,544 |
| Price / Earnings (TTM) | 14.19 |
| Price / Earnings (Forward) | 13.14 |
| Price / Sales | 1.76 |
| Price / Book | 1.42 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Profit Margin | 9.82% |
| Operating Margin (TTM) | 12.83% |
| Diluted EPS (TTM) | 9.71 |
| Quarterly Revenue Growth (YOY) | -4.80% |
| Quarterly Earnings Growth (YOY) | 24.50% |
| Total Debt/Equity (MRQ) | 37.12% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 1.16 B |
| Levered Free Cash Flow (TTM) | 901.28 M |
| Return on Assets (TTM) | 4.35% |
| Return on Equity (TTM) | 8.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | ICON plc | Bullish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 92.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bluespruce Investments, Lp | 31 Dec 2024 | 1,223,117 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 240.00 (Evercore ISI Group, 84.42%) | Buy |
| 240.00 (UBS, 84.42%) | Buy | |
| Median | 225.00 (72.89%) | |
| Low | 180.00 (Barclays, 38.31%) | Hold |
| Average | 220.43 (69.38%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 186.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 21 Aug 2025 | 200.00 (53.68%) | Hold | 175.70 |
| Barclays | 25 Jul 2025 | 180.00 (38.31%) | Hold | 187.01 |
| Evercore ISI Group | 25 Jul 2025 | 240.00 (84.42%) | Buy | 187.01 |
| 09 Jul 2025 | 170.00 (30.63%) | Buy | 150.53 | |
| Mizuho | 25 Jul 2025 | 225.00 (72.89%) | Buy | 187.01 |
| Truist Securities | 25 Jul 2025 | 234.00 (79.81%) | Buy | 187.01 |
| UBS | 25 Jul 2025 | 240.00 (84.42%) | Buy | 187.01 |
| Baird | 24 Jul 2025 | 224.00 (72.12%) | Buy | 195.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jul 2025 | Announcement | ICON Announces Results of Annual General Meeting |
| 23 Jul 2025 | Announcement | ICON Reports Second Quarter 2025 Results |
| 16 Jul 2025 | Announcement | ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report |
| 07 Jul 2025 | Announcement | ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability |
| 23 Jun 2025 | Announcement | ICON plc Schedules Second Quarter 2025 Earnings Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |